United States

People: G1 Therapeutics Inc (GTHX.OQ)

GTHX.OQ on NASDAQ Stock Exchange Global Select Market

4:00pm EDT
Change (% chg)

$0.05 (+0.31%)
Prev Close
Day's High
Day's Low
Avg. Vol
52-wk High
52-wk Low

Velleca, Mark 

Mr. Mark A. Velleca, M.D., Ph.D., is the President, Chief Executive Officer, Director of G1 Therapeutics Inc. Dr. Velleca has served as our Chief Executive Officer, President and a member of our board of directors since May 2014. Prior to joining us, Dr. Velleca was a co-founder and served as Senior Vice President of CGI Pharmaceuticals, Inc., or CGI, a biopharmaceutical company, from 1999 to 2010, where he managed the company from its inception through clinical trials of multiple drug candidates. After CGI was acquired by Gilead Sciences, Inc., or Gilead, a biotechnology company, in 2010, Dr. Velleca served as a Senior Advisor to Gilead from 2010 to April 2012, where he worked to help build its oncology pipeline. Dr. Velleca has served on the board of directors of BioMarker Strategies, a private oncology diagnostics company, from 2010 to 2012, and on the scientific advisory boards of BioRelix Inc., a biopharmaceutical company, from 2007 to 2012 and Intellikine, Inc., a biopharmaceutical company, from 2007 to 2010. Dr. Velleca most recently served as Executive Vice President at The Leukemia & Lymphoma Society from April 2012 to April 2014. Dr. Velleca also served as an attending physician at Yale New Haven Hospital and on the faculty of the Yale University School of Medicine. Dr. Velleca received his B.S. from Yale University, and his M.D. and Ph.D. from Washington University in St. Louis. We believe that Dr. Velleca’s perspective and experience as our Chief Executive Officer and President, as well as his depth of experience in the biotechnology industry, provide him with the qualifications and skills to serve on our board of directors.

Basic Compensation

Total Annual Compensation, USD 730,117
Restricted Stock Awards, USD --
Long-Term Incentive Plans, USD --
All Other, USD 8,100
Fiscal Year Total, USD 738,217

Options Compensation

  Quantity Market Value
Exercisable -- --
Unexercisable -- --
Exercised -- --
Name Fiscal Year Total

Seth Rudnick


Mark Velleca


Barclay Phillips


Rajesh Malik


Terry Murdock


Jay Strum

As Of  30 Dec 2017